Leerink Partnrs Issues Pessimistic Outlook for NAMS Earnings

NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) - Equities research analysts at Leerink Partnrs decreased their FY2028 earnings estimates for NewAmsterdam Pharma in a research note issued on Thursday, February 27th. Leerink Partnrs analyst R. Ruiz now forecasts that the company will post earnings per share of $0.40 for the year, down from their previous estimate of $0.42. The consensus estimate for NewAmsterdam Pharma's current full-year earnings is ($1.75) per share.

A number of other research analysts have also commented on NAMS. HC Wainwright reaffirmed a "buy" rating and set a $48.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Scotiabank boosted their target price on NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a "sector outperform" rating in a research note on Thursday, February 27th. Needham & Company LLC dropped their price target on NewAmsterdam Pharma from $46.00 to $42.00 and set a "buy" rating for the company in a research note on Thursday, February 27th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $43.80.

NewAmsterdam Pharma Price Performance

NewAmsterdam Pharma stock traded up $0.59 during trading hours on Monday, reaching $23.61. The stock had a trading volume of 965,829 shares, compared to its average volume of 455,925. The stock has a market cap of $2.18 billion, a PE ratio of -9.06 and a beta of -0.06. The company has a fifty day simple moving average of $22.30 and a 200-day simple moving average of $20.41. NewAmsterdam Pharma has a 52 week low of $15.19 and a 52 week high of $27.29.

Remove Ads

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The company had revenue of $12.77 million during the quarter, compared to the consensus estimate of $3.30 million.

Insider Transactions at NewAmsterdam Pharma

In other news, CAO Louise Frederika Kooij sold 150,000 shares of the company's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total value of $3,055,500.00. Following the sale, the chief accounting officer now directly owns 15,000 shares of the company's stock, valued at $305,550. This represents a 90.91 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Nap B.V. Forgrowth sold 100,728 shares of the stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $26.10, for a total transaction of $2,629,000.80. Following the completion of the transaction, the insider now owns 10,908,502 shares of the company's stock, valued at approximately $284,711,902.20. The trade was a 0.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 554,927 shares of company stock valued at $13,446,287. Corporate insiders own 19.50% of the company's stock.

Hedge Funds Weigh In On NewAmsterdam Pharma

Large investors have recently made changes to their positions in the business. GF Fund Management CO. LTD. bought a new position in NewAmsterdam Pharma during the 4th quarter valued at approximately $50,000. National Bank of Canada FI purchased a new stake in shares of NewAmsterdam Pharma in the fourth quarter worth $51,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of NewAmsterdam Pharma in the fourth quarter worth $80,000. KLP Kapitalforvaltning AS bought a new position in shares of NewAmsterdam Pharma during the fourth quarter valued at $154,000. Finally, Quarry LP raised its position in shares of NewAmsterdam Pharma by 2,469.2% in the 3rd quarter. Quarry LP now owns 6,500 shares of the company's stock worth $108,000 after purchasing an additional 6,247 shares during the last quarter. 89.89% of the stock is currently owned by hedge funds and other institutional investors.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.